Funder
HTA office of Iran Ministry of Health and Medical Education
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference44 articles.
1. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ (Clinical research ed). 2004;329(7472):972–5.
2. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. WHO guide to cost-effectiveness analysis. 2012.
3. Eichler H-G, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–28.
4. Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ. 2015;24(10):1289–301.
5. Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C, et al. Estimating a WTP-based value of a QALY: the ‘chained’ approach. Soc Sci Med. 1982;2013(92):92–104.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献